• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Therapeutic advances in medical oncology

    Therapeutic advances in medical oncology

    JournalISSN 1758-8340eISSN 1758-8359中科院 医学 2区

    年发文量

    研究主题

    论文(4622)

    排序
    1The Evolving Management of Patients with Extensive-Stage Small Cell Lung Cancer in Switzerland: from Regulatory Access to Bedside
    Nuria Neisy Mederos Alfonso, Ulrich Richter,Michael Thomas Mark, Sebastian Kraus, Alexander Meisel, Jana Pankovics,Martina Imbimbo,Patrizia Froesch,Kira-Lee Koster,Sabine Schmid,Sacha I. Rothschild,Alex Friedlaender,

    Extensive-stage small cell lung cancer (ES-SCLC) remains one of the most aggressive malignancies, with five-year survival historically below 10% despite recent therapeutic advances. Chemo-immunotherapy has reshaped first-line treatment, but in Switzerland, the impact of innovation in routine care also depends on healthcare system structures, regulatory pathways, and reimbursement mechanisms. This narrative, expert-informed review examines ES-SCLC management in Switzerland using Swiss registry data, peer-reviewed literature, guidelines, and Swiss policy and regulatory sources. Evidence was selected for clinical and Swiss-specific relevance, with emphasis on literature from the chemo-immunotherapy era, real-world evidence, and access pathways relevant to Swiss practice. ES-SCLC management in Switzerland is evolving from chemo-immunotherapy-based first-line care toward maintenance intensification, emerging later-line options, and efforts toward more personalized treatment strategies. Switzerland has acted as an early adopter of selected innovations, including the first European approval of lurbinectedin plus atezolizumab for first-line maintenance, and, more recently, Swissmedic authorization of tarlatamab as the first DLL3-directed T-cell engager for previously treated ES-SCLC. The translation of clinical evidence into patient access is shaped by Swissmedic approval, FOPH reimbursement decisions, and Article 71 pathways, while persistent regional and reimbursement-related variation highlights remaining gaps. Switzerland illustrates how rapid regulatory adaptation can accelerate innovation in ES-SCLC, while also showing that decentralized healthcare systems must address reimbursement fragmentation and unequal implementation to translate scientific progress into equitable patient benefit.

    2026
    引用
    AI阅读
    加入学术空间
    2The Role of PD-L2 Within the PD-1-driven Axis in NSCLC: from Molecular Mechanisms to Clinical Translation
    Federico Pio Fabrizio,Sara Bravaccini, Giuseppe Angelico,Filippo Torrisi,Antonio Rossi

    The PD-1 (Programmed Death-1)/PD-L1 (Programmed Death-Ligand 1)/PD-L2 (Programmed Death-Ligand 2) axis underlies inhibitory signaling in the regulatory mechanisms of antitumor immunity in non-small cell lung cancer (NSCLC). Although PD-L1 is widely recognized as a predictive biomarker for PD-1/PD-L1 blockade, the molecular, histopathological, and regulatory characterization of PD-L2, as well as its potential clinical associations, remain to be defined. To date, the available evidence suggests that PD-L2 expression in NSCLC may be linked to a complex network involving diverse mechanisms, ranging from genetic and epigenetic factors to transcriptional, post-transcriptional mechanisms, all sharing a common denominator: the dysregulation of inflammatory and oncogenic signals underlying specific pathways that shape heterogeneous expression within and across different tumor subtypes. From an immunological perspective, PD-L2 has been implicated in the regulation of tumor immune evasion mechanisms by modulating T-cell activation and may contribute to an immunosuppressive state within the lung tumor microenvironment (TME), where various types of immune and stromal cell populations coexist and interact, including dendritic cells, fibroblasts, macrophages, and T cells. To date, molecular and histopathological studies have not yet fully clarified the role of PD-L2, but they point to a scenario in which the expression, distribution, and histopathological localization of this target are potentially distinct from those of PD-L1. Several underlying factors contribute to this variability, as well as heterogeneity of tumor phenotypes, differences in composition of cellular components within TME, the associated clinical characteristics that distinguish different subgroups of NSCLC patients and their responses to immuno-therapies. PD-L2 expression can also be found in PD-L1-negative NSCLC tumors, raising the hypothesis that it might contribute to patient stratification in the setting of immune checkpoint inhibition. However, current clinical evidence is very limited and does not establish a predictive role for PD-L2. This narrative review summarizes the current molecular, histo-pathological, and functional understanding of PD-L2 regulation across different NSCLC histologies, integrating emerging clinical data to address an unmet clinical need and provide a more up-to-date perspective that links biological mechanisms to increasingly relevant translational implications.

    2026
    引用
    AI阅读
    加入学术空间
    3Comparison of Efficacy and Safety of GP to PX Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Score–Matched Analysis
    Yutong Yin, Mengqi Guo, Tingting Wang,Zhiyuan Xu, Yue Xiao,Miaoying Cai,Yifu Wang,Huangrong Ma,Victor Ho-Fun Lee,Li Yang

    Background Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) is a standard treatment strategy for patients with locoregionally advanced nasopharyngeal carcinoma (LANPC). Gemcitabine plus cisplatin (GP) and capecitabine plus cisplatin (PX) are commonly used induction chemotherapy regimens; however, comparative real-world evidence regarding their efficacy and safety remains limited. Objectives This study aimed to compare the efficacy and safety of gemcitabine plus cisplatin (GP) to capecitabine plus cisplatin (PX) as induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC). Design Single-center, retrospective, observational cohort study. Methods We retrospectively analyzed 244 patients with locoregionally advanced NPC (LANPC) who received induction chemotherapy with either GP or PX, followed by radical concurrent chemoradiotherapy (CCRT) between 2015 and 2024 at our institution. Propensity score matching (PSM) was performed to balance baseline characteristics between the two treatment groups. Survival outcomes and acute treatment-related toxicities were compared. Results After 1:1 PSM, 166 patients were included (GP, n = 83; PX, n = 83), with a median follow-up of 64.2 months. No statistically significant differences were observed between the GP and PX groups in 3-year overall survival (96.2% vs. 91.5%, P = 0.200), progression-free survival (91.6% vs. 84.2%, P = 0.089), locoregional relapse-free survival (96.3% vs. 98.7%, P = 0.797), or distant metastasis-free survival (95.3% vs. 86.5%, P = 0.069). The GP group showed higher rates of grade ≥3 leukopenia (14.5% vs. 1.2%, P = 0.002), neutropenia (42.2% vs. 13.3%, P < 0.001), and thrombocytopenia (7.2% vs. 0.0%, P = 0.028). Electrolyte disturbances (21.7% vs. 8.4%, P = 0.03) and oral mucositis (41.0% vs. 19.3%, P = 0.004) occurred more frequently in the PX group. Advanced TNM stage (HR = 3.06, P = 0.007) was independently associated with an inferior PFS. Higher PNI was independently associated with a lower risk of progression (HR = 0.39, P= 0.011). Conclusions In this non-randomized retrospective study, no statistically significant differences in survival outcomes were observed between GP- and PX-based induction chemotherapy followed by CCRT. However, these two regimens exhibited distinctive toxicity profiles, which should be carefully considered when selecting induction chemotherapy in clinical practice. Prospective randomized trials are needed to establish their comparative efficacy and safety.

    2026
    引用
    AI阅读
    加入学术空间
    4The Tumor Stroma Ratio in Stage II and III Colon Cancer: Prognostic Impact and Evaluation of Predictive Value
    Floor Heilijgers, Marie-Christine E. Bakker,Ingrid A. Franken,Miriam Cuatrecasas,Koen C. M. J. Peeters,Hein Putter,Frank M. Speetjens,Jeanine M. L. Roodhart,Wilma E. Mesker

    Background Current pathological biomarkers and tumor-node-metastasis (TNM) staging provide limited precision for guiding adjuvant chemotherapy (ACT) in colon cancer. The Tumor Stroma Ratio (TSR) is a histopathological prognostic biomarker and may predict ACT benefit. Objectives This study evaluated the predictive value of TSR for ACT benefit in patients with stage II and III colon cancer from the UNITED trial and the Netherlands Cancer Registry. Design A retrospective cohort study using trial and real-world data. Methods TSR was assessed on H&E-stained slides from surgical resection specimens of stage II and III colon cancer patients and categorized as stroma-low (≤50%) or stroma-high (>50%). The primary endpoint was recurrence-free rate (RR). Disease-free survival (DFS) and overall survival (OS) were secondary outcomes. Missing data was handled using multiple imputation by chained equations. To adjust for baseline differences in the probability of receiving ACT, inverse probability of treatment weighting with stabilized weights was applied. Cox proportional hazards models were used to assess prognostic and predictive effects, including an interaction term between ACT and TSR. Results This study included 2980 patients; 57.1% received ACT and 38.9% were classified as stroma-high. Stroma-high patients demonstrated significant worse survival outcomes (RR: HR 1.85 with 95%CI 1.54 – 2.23, p <0.001; DFS: HR 1.61 with 95%CI 1.37 – 1.90, p <0.001; OS: HR 1.67 with 95%CI 1.37 – 2.04, p <0.001). In absolute terms, ACT was associated with a larger survival benefit and more favorable number needed to treat (NNT) in stroma-high patients (72% vs. 58%; NNT = 7) than in stroma-low patients (85% vs. 78%; NNT = 14). However, no statistically significant interaction was observed between TSR and ACT for survival outcomes. Conclusions TSR remains a strong independent prognostic factor for survival outcomes and a reliable marker of adverse tumor biology. Differential absolute benefit from ACT was seen between stroma-low and stroma-high patients, reflected by a more favorable NNT and likely due to the poorer prognosis of stroma-high patients without ACT. No predictive value of TSR was demonstrated in this study. Integration of TSR into clinical practice may aid in refining risk assessment and thereby ACT decision-making.

    2026
    引用
    AI阅读
    加入学术空间
    5Muscle and Tissue Radiodensity Matter: Automated CT-based Body Composition Analysis Predicts Survival in Hepatocellular Carcinoma Patients Undergoing Degradable Starch Microspheres Transarterial Chemoembolization (DSM-TACE)
    Leonie S. Jochheim, Hannah L. Steinberg, Amos C. Zeller,Jan Best,Jens M. Theysohn, Gilbert Rahe,Benedikt M. Schaarschmidt,Christoph Schramm,Johannes Haubold,Hartmut Schmidt,Johannes M. Ludwig

    Background Transarterial chemoembolization with degradable starch microspheres (DSM-TACE) has emerged as an increasingly important and effective treatment for hepatocellular carcinoma (HCC); however, the impact of body composition on clinical outcomes remains unknown. Objectives This study aimed to assess the prognostic significance of pretreatment, fully automated 3D-volumetric computed tomography (CT)-based body composition analysis (BCA) in patients with HCC undergoing DSM-TACE. Design Retrospective single-center study. Methods A total of 137 patients were treated with repetitive DSM-TACE. BCA quantified the volumes and radiodensities of the skeletal muscle (SM), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and bone (B) using baseline abdominal CT scans. The maximally selected log-rank test was applied for the cutoff selection. Survival outcomes were analyzed using Kaplan-Meier curves and uni- and multivariate Cox proportional hazards models with hazard ratios (HR). Results The median overall survival (OS) of the cohort was 16.5 months. Multivariate analysis identified three BCA parameters as independent predictors of improved survival: a high SM/B ratio (HR: 0.44; p = 0.008), high SM radiodensity (HR: 0.26; p = 0.004), and low VAT radiodensity (HR: 0.20; p = 0.004). A cumulative risk score based on these independent factors (1 point per favorable factor) allowed for distinct survival stratification ( p < 0.0001), with median OS ranging from 34.4 months in the low-risk group (score 3) to 17.7, 10.1, and 2.8 months for scores of two to zero points (pairwise comparison p ≤ 0.016). Survival stratification remained statistically significant in both the Barcelona Clinic Liver Cancer (BCLC) stage B and C subgroups. Conclusion Fully automated CT-based quantification of body composition is a valuable tool for assessing survival in patients with HCC treated with DSM-TACE. The integration of the SM/B ratio and tissue radiodensities enable can improve personalized survival stratification within the BCLC B and C subgroups, warranting further validation and clinical integration evaluation.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4622 篇论文

    高被引作者

    作者引用发文
    Shu Chuen Li24943
    Sklar Grant Edward23301
    Vernon Min Sen Oh23301
    Ming-Sound Tsao11917
    Ioannis Bellos9681
    Summer L Williams9281
    Kelly B. Haskard9281
    Dimatteo M Robin9281
    Leslie R. Martin9281
    Shawna Organ7921

    高产作者

    作者引用发文
    Antonio Russo39019
    Quan Zhou58316
    Viviana Bazan30914
    Pascal C. Hammel6513
    Yukio Nakamura14813
    Cheng-Hao Weng16812
    Razelle Kurzrock3912
    Lorena Incorvaia27912
    Jun Iwamoto19712
    Hiroyuki Kato14312

    相关期刊

    American journal of clinical oncology
    Canadian operating room nursing journal
    Cancer Treatment Reviews
    Journal of Cancer Research and Clinical Oncology
    Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology
    Expert review of anticancer therapy
    Critical Reviews in Oncology/Hematology
    ESMO Open
    Future Oncology
    Cancer Treatment and Research Communications